Muthusamy Jayaraman
Overview
Explore the profile of Muthusamy Jayaraman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
4351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al.
Drug Metab Dispos
. 2021 Jun;
50(6):781-797.
PMID: 34154993
Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to -acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, and with the recent approvals of...
2.
Brown C, Gupta S, Qin J, Racie T, He G, Lentini S, et al.
Nucleic Acids Res
. 2020 Aug;
48(21):11827-11844.
PMID: 32808038
One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist for months in preclinical species and humans. Here, we investigated the underlying biology supporting...
3.
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc A, Maier M, Manoharan M, FitzGerald K, Jayaraman M, Barros S, et al.
Nat Nanotechnol
. 2019 Dec;
14(12):1084-1087.
PMID: 31802031
No abstract available.
4.
Schlegel M, Foster D, Kelin A, Zlatev I, Bisbe A, Jayaraman M, et al.
J Am Chem Soc
. 2017 Jun;
139(25):8537-8546.
PMID: 28570818
Here we report the investigation of glycol nucleic acid (GNA), an acyclic nucleic acid analogue, as a modification of siRNA duplexes. We evaluated the impact of (S)- or (R)-GNA nucleotide...
5.
Kelin A, Zlatev I, Harp J, Jayaraman M, Bisbe A, OShea J, et al.
J Org Chem
. 2016 Mar;
81(6):2261-79.
PMID: 26940174
Although judicious use of chemical modifications has contributed to the success of nucleic acid therapeutics, poor systemic stability remains a major hurdle. The introduction of functional groups around the phosphate...
6.
Rajeev K, Nair J, Jayaraman M, Charisse K, Taneja N, OShea J, et al.
Chembiochem
. 2015 Mar;
16(6):903-8.
PMID: 25786782
We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR). Novel monovalent GalNAc...
7.
Mui B, Tam Y, Jayaraman M, Ansell S, Du X, Tam Y, et al.
Mol Ther Nucleic Acids
. 2013 Dec;
2:e139.
PMID: 24345865
Lipid nanoparticles (LNPs) encapsulating short interfering RNAs that target hepatic genes are advancing through clinical trials, and early results indicate the excellent gene silencing observed in rodents and nonhuman primates...
8.
Maier M, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, et al.
Mol Ther
. 2013 Jun;
21(8):1570-8.
PMID: 23799535
In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have advanced into human clinical trials. The results from these early clinical trials suggest that lipid...
9.
Prakash T, Lima W, Murray H, Elbashir S, Cantley W, Foster D, et al.
ACS Chem Biol
. 2013 Apr;
8(7):1402-6.
PMID: 23614580
We evaluated the abilities of an antisense oligonucleotide (ASO), a small interfering RNA (siRNA), and a single-stranded siRNA (ss-siRNA) to inhibit expression from the PTEN gene in mice when formulated...
10.
Novobrantseva T, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, et al.
Mol Ther Nucleic Acids
. 2013 Jan;
1:e4.
PMID: 23344621
Leukocytes are central regulators of inflammation and the target cells of therapies for key diseases, including autoimmune, cardiovascular, and malignant disorders. Efficient in vivo delivery of small interfering RNA (siRNA)...